EU/3/14/1303

About

On 29 July 2014, orphan designation (EU/3/14/1303) was granted by the European Commission to AstraZeneca AB, Sweden, for cediranib for the treatment of ovarian cancer.

Key facts

Active substance
Cediranib
Disease / condition
Treatment of ovarian cancer
Date of first decision
29/07/2014
Outcome
Positive
EU designation number
EU/3/14/1303

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

AstraZeneca AB                                                                                                 
SE-151 85 Södertälje
Sweden
Tel:+46 8 553 275 91
Fax: +46 8 553 269 04
E-mail: orphandrugs@astrazeneca.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating